Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
568 articles by Ben Fidler
-
CRISPR eyes autoimmune disease in revamp of cell therapy plans
Dec. 5, 2023 -
Roche joins obesity drug chase with $2.7B deal for startup Carmot
Dec. 4, 2023 -
Adlai Nortye IPO gives old Novartis cancer drug new life
Sept. 29, 2023 -
Beam begins US testing of first-of-its-kind ‘base editing’ cancer drug
Sept. 5, 2023 -
Roche claims study success for targeted drug in early lung cancer
Sept. 1, 2023 -
Bristol Myers gets key FDA approval for bone marrow disease drug
Aug. 29, 2023 -
Apellis to lay off 25% of staff, trim research in major restructuring
Aug. 29, 2023 -
‘Project NextGen’ to spend $1.4B in search for better COVID drugs, vaccines
Aug. 22, 2023 -
Fulcrum rejoins sickle cell drug race as FDA lifts study hold
Aug. 22, 2023 -
Regeneron rebounds to win FDA OK for longer-lasting vision loss drug
Aug. 21, 2023 -
Precision sells lymphoma drug to Imugene in retreat from cell therapy research
Aug. 16, 2023 -
Radiopharmaceuticals for cancer: Making radiation precise
Aug. 15, 2023 -
J&J joins PARP rivals with narrow FDA clearance in prostate cancer
Aug. 14, 2023 -
HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
Aug. 10, 2023 -
Biopharma sector still growing despite layoff wave, Stifel report finds
Aug. 7, 2023 -
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
Aug. 5, 2023 -
Regeneron gets ‘clarity’ in plan to defend top-selling eye drug, but is set back elsewhere
Aug. 4, 2023 -
Sarepta offers early look at closely watched gene therapy launch
Aug. 3, 2023 -
Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy
Aug. 3, 2023 -
EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing
Aug. 1, 2023 -
Apellis faces safety doubts for fast-selling eye drug
July 31, 2023 -
AstraZeneca buys Pfizer’s early gene therapy work for up to $1B
July 28, 2023 -
Kincell spins out of cell therapy biotech, joining wave of manufacturing startups
July 26, 2023 -
Infinity to lay off staff, offload cancer drug after merger falls apart
July 26, 2023 -
Stoke faces new doubts in search for ‘Spinraza for epilepsy’
July 25, 2023